Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Tender notice |
| Buyer: | BRISTOL & WESTON NHS PURCHASING CONSORTIUM |
| Main Category: | Goods |
| Procurement Method: | Open procedure (above threshold) |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): |
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
20 November 2024
Closed
Estimated Value
£525,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| £525,000 |
| Release Date: | 21 October 2024 |
| Application Deadline: | 20 November 2024 |
| Procurement ID (OCID): | ocds-b5fd17-b2a4d53c-1ad7-47fe-9e74-05828692ff5c |
| Notice Reference: | 94bc69ca-e4f7-41a3-acdd-9530bfed2e07-795595 |
All 3 notices for this procurement, oldest first.
Blood Extraction Platform
Blood Extraction Platform
Blood Extraction Platform
Earlier notices predate the Procurement Act 2023 (commenced 24 Feb 2025) and therefore don't carry UK1–UK17 codes.
View Original Notice
Access the full notice on the official portal
This contract is for 6 years with an options 1 year extension. Full details are provided in the Invitation To Tender pack. This is provided in the SAP Ariba portal. In 2018 NHSE commissioned Genomic Laboratory Hubs (GLHs) for the delivery of high-quality, efficient, and centralised genomic services. The South West GLH is hosted at NBT, all core rare disease, cancer testing and specialised rare disease testing in cardiology, renal and neurology is provided from the Bristol Genetics laboratory (BGL). The purpose of this notice is to alert potential suppliers to an opportunity to provide a high throughput DNA extraction platform capable of extracting DNA from venous blood where sample volumes are greater than 2ml and be able to produce a high yield of high molecular weight (>48kb) genomic DNA to BGL. The system must produce minimum DNA yields which average between 40 and 100 micrograms of DNA from 2-10ml of human blood. This is key to ensure that the platform can meet the requirements of our Facioscapulohumeral muscular dystrophy (FSHD) service for which 95% of diagnoses are made through genomic testing using Southern Blotting. The total funding available for this capital equipment procurement is £350,000 (inclusive of VAT) however reagent and consumable costs will also be taken into consideration when assessing the Whole Life Cost of the award. Additional requirements include; - The platform should be high throughput with flexibility in batch sizes for efficient use. These should range from a single sample to maximum batch size. - The system must allow the use of a variety of tube types in which the extracted DNA can be collected or eluted into, in particular 2ml screw-cap tubes and 2D barcoded tubes (e.g. fluidX 0.7ml tubes). - Cross-contamination of samples during automated processing must be shown to be absent - The system must incorporate barcode scanning and be able to record the barcode labels of both primary tubes and DNA output tubes in a log or database. - The system must be able to use barcoding data to match the input tube with the output tube and complete elution of DNA according to this information. - The system must be capable of automating extraction procedure to a level where 'walkaway' operation is facilitated - The system must be capable of sampling from the primary tube starting material (blood)- avoiding the need to manually aspirate from the primary sample tube - The system must be enclosed in such a way to protect the operators.
Document pack· 1 file
Refrigeration, Air-conditioning and Chillers PPMs, reactive maintenance, repair work (HVAC tender)
BRISTOL & WESTON NHS PURCHASING CONSORTIUM · WAC-27397
PSDS Wave 3 - Cascade Heat Pumps
BRISTOL & WESTON NHS PURCHASING CONSORTIUM · WAC-49021
Blood Extraction Platform
BRISTOL & WESTON NHS PURCHASING CONSORTIUM · WAC-383545